Category: 3. Business

  • Shionogi Expands Rare Disease Presence with Planned Acquisition of Global Rights to Tanabe Pharma Corporation’s RADICAVA ORS® (edaravone) and IV RADICAVA

    OSAKA, Japan, December 22, 2025 Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced that its Board of Directors, at a meeting held on December 22, 2025, resolved to acquire a newly established company that Tanabe Pharma Corporation (Head Office: Osaka, Japan; Chief Executive Officer: Akihisa Harada; hereafter “Tanabe Pharma”) will create to hold the rights to RADICAVA ORS® (edaravone) and IV RADICAVA. Tanabe Pharma plans to form this new entity, and Shionogi intends to purchase 100% of its shares. The agreement between Shionogi and Tanabe Pharma was signed this afternoon. As part of the transaction, a new business company established by Tanabe for RADICAVA in the U.S. will become a wholly owned subsidiary of Shionogi Inc.

     

    RADICAVA ORS is approved by the U.S. Food and Drug Administration (FDA) and other regulatory agencies around the world for the treatment of amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease for which there is no cure and few treatment options. RADICAVA ORS, along with a previously available intravenous formulation, have been used to treat more than 20,000 people with ALS in the U.S. to date. 

     

    “We are pleased to welcome RADICAVA to Shionogi. This critically important medicine was created to reduce the devastating burden of ALS, and we are honored to assume responsibility for it and to sustain and grow the relationships Tanabe Pharma has established with the patient and healthcare communities in the U.S.,” said Isao Teshirogi, Ph.D., CEO of Shionogi. “We recognize the significant responsibility that comes with a widely utilized breakthrough medicine and will be conscientious stewards of this important drug.”   

     

    “We are very excited to welcome this team and outstanding medicine to our U.S. business. This planned acquisition will solidify our strategic focus in rare disease and immediately add capabilities to ensure long term success in this important category,” said Nathan McCutcheon, President and CEO, Shionogi Inc. “Going forward, this infrastructure will support future launches in rare disease including Shionogi’s development programs in Fragile X syndrome, Jordan’s Syndrome and Pompe disease.” 

     

    Purpose and Background of the Acquisition

     

    Shionogi has identified “Contributing to a Healthy and Enriched Life” as a materiality (key issue) to address in order to create new value for customers and society. To realize a society where everyone can live vibrantly and true to themselves, we have designated disease areas with significant anticipated future unmet needs—classified as “high social impact QOL disorders” (such as sleep disorders, hearing loss, and rare diseases)—as priority areas for research and development, and we are advancing initiatives to deliver solutions.

     

    Within the category of high social impact QOL disorders, Shionogi is establishing a presence in rare disease through existing research programs in Fragile X syndrome, Jordan’s syndrome and Pompe disease. In addition to potential early phase rare disease assets that recently became part of Shionogi’s pipeline,1 this acquisition creates the commercial infrastructure to accelerate delivery of new rare disease medicines once regulatory approvals are obtained. 

     

    Key Assets and Capabilities to Be Secured Through This Acquisition

    • Acquisition of all rights, including global marketing rights for RADICAVA ORS® and IV RADICAVA
    • Establishing a strong rare disease commercial platform in the U.S. market
    • Integration of talent and business expertise in the rare disease area

     

    Under this agreement, Shionogi will pay a lump sum of USD 2.5 billion to Tanabe Pharma through Shionogi Inc., upon completion of the procedures. Additionally, Shionogi may pay a royalty on future sales, subject to certain conditions. Going forward, the RADICAVA ORS® and IV RADICAVA business company will commence operations as a wholly owned subsidiary of Shionogi Inc.

     

    1.     Resolution Date of Board Meeting

    December 22, 2025

     

    2.     Agreement Date

    December 22, 2025

     

    3.     Target Closing Date

    On or after April 1, 2026 (Scheduled)

     

    4.     Future Prospects

    The impact of making this company a wholly owned subsidiary on Shionogi’s consolidated financial results for the fiscal year ending March 31, 2026 is expected to be immaterial.

     

    Advisors

    Cleary Gottlieb Steen & Hamilton LLP served as legal advisor to Shionogi. Centerview Partners LLC served as lead financial advisor and Ropes & Gray LLP served as legal advisor to Tanabe. Goldman Sachs also provided financial advice to Tanabe. Bank of America served as financial advisor to Bain Capital.

     

    About RADICAVA ORS® (edaravone)
    RADICAVA ORS received approval from the U.S. Food and Drug Administration (FDA) in 2022 for the treatment of amyotrophic lateral sclerosis (ALS), a progressive neurogenerative disease for which there is no cure and few treatment options. In 2024, FDA granted RADICAVA ORS Orphan Drug Exclusivity based on its major contribution to patient care by providing an oral suspension route of administration that avoids the burdens of IV administration. To date, in the U.S., RADICAVA ORS, along with the previously available intravenous formulation have been used to treat nearly 20,000 people with ALS.

     

    Edaravone was discovered and developed for ALS by Mitsubishi Tanabe Pharma Corporation (MTPC) and commercialized in the U.S. by Mitsubishi Tanabe Pharma America, Inc. (MTPA). The MTPC group companies began researching ALS in 2001 through an iterative clinical platform over a 13-year period. In 2015, edaravone was approved as RADICUT® for the treatment of ALS in Japan and South Korea. Marketing authorizations were subsequently granted in Canada (October 2018), Switzerland (January 2019), Indonesia (July 2020), Thailand (April 2021), Malaysia (December 2021), Australia (February 2023) and Brazil (February 2024). Marketing authorization for RADICAVA® Oral Suspension was granted in Canada (November 2022) and Switzerland (May 2023), and RADICUT® Oral Suspension 2.1% was granted regulatory approval in Japan in December 2022.

     

    【About ALS】

    ALS (Amyotrophic Lateral Sclerosis) is a progressive neurodegenerative disease characterized by the selective degeneration and loss of motor neurons, leading to muscle weakness and respiratory impairment. After onset, muscle atrophy gradually progresses, and ultimately respiratory muscle paralysis severely impacts life expectancy. Globally, the annual incidence is estimated at approximately 1–2 cases per 100,000 population, making it a rare disease for which no fundamental cure currently exists.2 Multiple factors, including oxidative stress and glutamate-induced excitotoxicity, are involved in its pathophysiology, and treatment options to slow disease progression remain extremely limited. For this reason, ALS is recognized as a disease with a high level of unmet medical need, and the development and delivery of innovative therapies are strongly required.

     

    About Tanabe Pharma America, Inc.

    Based in Jersey City, N.J., Tanabe Pharma America, Inc. (TPA) is a wholly-owned subsidiary of Tanabe Pharma Corporation. It was established by Tanabe Pharma Corporation to develop and advance our pipeline as well as commercialize approved pharmaceutical products in North America. For more information, please visit https://us.tanabe-pharma.com or follow us on X (formerly Twitter), Facebook and LinkedIn.

     

    About Tanabe Pharma Corporation, Inc.

    Tanabe Pharma Corporation is one of the oldest pharmaceutical companies in the world, founded in 1678. Tanabe Pharma is headquartered in Doshomachi, Osaka, the birthplace of Japan’s pharmaceutical industry. Tanabe Pharma sets the MISSION of “Creating hope for all facing illness.” To that end, Tanabe Pharma is working on the disease areas of central nervous system, immuno-inflammation, diabetes and kidney, and cancer. Tanabe Pharma is focusing on “precision medicine” to provide drugs with high treatment satisfaction and additionally working to develop “around the pill solutions” to address specific patient concerns based on therapeutic medicine, including prevention of diseases, pre-symptomatic disease care, prevention of aggravation and prognosis. For more information, go to https://www.tanabe-pharma.com/en/index.html.

     

    About Shionogi in Rare Disease

    Shionogi is committed to the research and development of innovative medicines that address unmet medical needs for people worldwide. Rare diseases often have limited treatment options and affect the daily lives of individuals and families around the world. In the U.S., Shionogi is advancing clinical programs for rare diseases and disorders including Fragile X syndrome, Jordan’s Syndrome and Pompe disease. For more information, view our pipeline here: https://www.shionogi.com/us/en/innovation/pipeline.html.

     

    About Shionogi & Co., Ltd.

    Shionogi & Co., Ltd. is a leading global research-driven pharmaceutical company dedicated to bringing benefits to patients based on its corporate philosophy of “supplying the best possible medicine to protect the health and well-being of the patients we serve.” Shionogi has discovered and developed novel antibiotics, medicines for HIV and influenza, and currently markets medicines for infectious diseases and central nervous system disorders. Shionogi’s global pipeline includes research programs in infectious disease, pain/CNS, metabolic disorders, rare disease, oncology and stroke. For more information, visit https://www.shionogi.com/global/en. 

     

    References

    1.       Press Release: December 1, 2025:
    Notice regarding Completion of Succession of Japan Tobacco Inc.’s Pharmaceutical Business through Simplified Absorption-Type Company Split

    2.       Xu, et al. Global variation in prevalence and incidence of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol. 2020 Apr;267(4):944-953. DOI: 10.1007/s00415-019-09652-y

     

    Forward-Looking Statements

    This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

     

    For Further Information, Contact:

    SHIONOGI Website Inquiry Form: https://www.shionogi.com/global/en/contact.html

    Shionogi Inc.: ShionogiCommunications@shionogi.com

    Shionogi Europe Press Office: pressoffice@shionogi.eu

     

     

    Continue Reading

  • Afadin-deficient mouse retinas exhibit severe neuronal lamination defects but preserve visual functions

    Afadin-deficient mouse retinas exhibit severe neuronal lamination defects but preserve visual functions

    Immunohistochemical analysis was performed as described previously (Hori et al., 2019; Kubo et al., 2021). In brief, the retina used for MEA recordings and isolated mice eyes was fixed with 4% PFA in PBS for 30 min at room temperature. After three-time washes, retinas were cryoprotected by 30% sucrose in PBS overnight, embedded in an OCT compound (Sakura, Japan), frozen on dry ice, and sectioned at 20  μm of thickness. Whole-mount immunostaining was performed as previously described with some modifications (Ueno et al., 2018). The retinas were gently peeled off from the sclera, fixed with 4% PFA in PBS for 30 min at room temperature, and washed three times. Retinal sections and whole retinas were soaked in blocking buffer (5% NDS, 0.1% Triton X-100, in 1x PBS) for 1–2 hr at room temperature and incubated with primary antibodies in blocking buffer 1 or 2 overnight at 4°C. The sections were washed with PBS three times and incubated with fluorescent dye-conjugated secondary antibodies and DAPI (1:1000) for more than 2 hr at room temperature or overnight at 4°C under the light-shielded condition. The specimens were observed using a laser confocal microscope (LSM900; Carl Zeiss, Germany). For BrdU staining, mice were given an intraperitoneal injection of 20 mg/kg BrdU and sacrificed 2 hr later. Retinal sections were then pretreated with 2 N HCl at 37°C for 30 min before blocking. The antibodies and dilution ratios were as follows: anti-l-afadin (ab90809, Abcam, UK, 1:100), anti-nectin1 (D146-3, MBL, Japan, 1:100), anti-nectin2 (D083-3, MBL, Japan, 1:100), anti-nectin3 (D084-3, MBL, Japan, 1:100), anti-PKCα (P5704, Sigma, USA, 1:1000, P4334, Sigma, 1:10,000), anti-SCGN (AF4878, R&D systems, USA, 1:2000), anti-Arr3 (AB15282, Millipore, USA, 1:1000), anti-Calbindin (PC253L-100, Millipore, USA, 1:200), anti-ChAT (AB144P, Millipore, USA, 1:50), anti-Bassoon (SAP7F407, Enzo, USA, 1:1000), anti-mGluR6 (current study, 1:3000), anti-PSD95 (#124 014, Synaptic Systems, Germany, 1:3000), anti-GluR5 (Grik1, gift from Steve H DeVries, 1:2000), anti-PKARIIβ (#610625, BD biosciences, USA, 1:500), anti-Calretinin (PC235L-100UCN, Millipore, USA, 1:5000), anti-EAAT5 (HPA049124, Sigma, USA, 1:100), anti-vGlut1 (AB5905, Millipore, USA, 1:6000), anti-HPC-1 (S0664, Sigma, USA, 1:10000), anti-active caspase3 (AF835, R&D Systems, USA, 1:300), anti-Chx10 (Hori et al., 2019, 1:100), anti-Otx2 (AF1979, R&D systems, USA, 1:200), anti-Glutamine synthetase (GS, MAB302, Millipore, USA, 1:500), anti-CD31 (#557355, BD Biosciences, USA, 1:100), anti-Lhx2 (sc-19344, Santa Cruz Biotechnology, USA, 1:100), anti-RBPMS (GTX118619, GeneTex, USA, 1:500), anti-Ki67 (#556003, BD Biosciences, USA, 1:100), anti-Tuj1 (#801201, BioLgend, USA, 1:500), anti-AP2α (3B5-c, DSHB, USA, 1:1000), anti-Rom1 (gift from Robert Moldey, 1:10), anti-Rhodopsin (STJ95452, ST John’s Laboratory, UK, 1:100), anti-S-opsin (sc-14363, Santa Cruz Biotechnology, USA, 1:500), anti-M-opsin (AB5405, Sigma, USA, 1:500), anti-GFP (GFP-1010, Aves labs, USA, 1:1000), anti-β-catenin (#610153, BD Biosciences, USA, 1:1000), anti-N-cadherin (#610920, BD Transduction Laboratories, USA, 1:500), anti-BrdU (#347580, BD Biosciences, USA, 1:100), and anti-phospho-histone H3S10 (#06–570, Millipore, USA, 1:2000) antibodies.

    Continue Reading

  • Martyn’s Law Regulator preparations – GOV.UK

    Martyn’s Law Regulator preparations – GOV.UK

    Since July this year I have had the privilege to occupy the position of Interim Executive Director for Martyn’s Law in the SIA. As I prepare to hand over to the new substantive Director in January, I wanted to take the opportunity to reflect on the last 6 months.

    Almost as soon as the critical foundation work on the development of the regulatory blueprint had finished, the SIA, working closely with colleagues in the Home Office, moved into the mobilisation phase of the programme, with the key objective of ensuring that the regulation of Martyn’s Law is highly effective and delivers a positive impact on public safety.   

    During this period, I have led an experienced team comprising technical expertise and those with extensive experience in regulation and the development of regulatory models. This has included secondments from well-established, respected UK regulatory bodies who have led on the development of the inspections and assessment pilot workstream and the evolution of the Risk Assessment Framework.

    We have worked in tandem with colleagues from the Homeland Security Group to manage the critical interdependencies between policy, regulations, and the operational elements of the regulatory model. The quality of this work has been further enhanced by the considerable contribution made from our protective security partners. Their willingness to assist has never wavered and I am very grateful for their continued support.

    There is no doubt this has been an intensive, fast-paced period which has seen extensive progress made across 6 major projects and 33 workstreams. Whilst recruitment has been ongoing to fill senior posts within the regulator, myself and the team have pressed on to ensure that the development of the Target Operating Model, the Standard Operating Procedures for the regulatory functions, the role requirements for the new posts, the development of the competency based training programme, and the recruitment strategy to bring in talent at the earliest juncture has continued unhindered.

    I recognise the significant value in engaging with the regulated community and other key stakeholders and to that end we have worked closely with the Homeland Security Group to deliver over 20 webinars covering 10 sectors and reaching nearly 6,000 individuals in scope of the Private Security Industry Act. Sectors have included but have not been limited to: retail, hospitality, nighttime economy, visitor attractions, local authorities, healthcare, and education.

    Regular event attendance has included thousands more individuals reached through trade association conferences, the International Security Expo and National Association of Healthcare Security Conference and the Institute of Licensing Conference. Our joint presence has been welcomed by stakeholders, and we continue to maximise opportunities to target those in scope via our networks.

    In the coming months we will continue our work to advise, support, and assist those in the regulated community. The scope of our engagement will widen to include other regulatory bodies and enforcement agencies operating in the same landscape such as local authorities, fire services, the Sports Ground Safety Authority, and policing. Whilst the regulatory focus under Martyn’s Law is narrow, we are mindful of the need to avoid excessive regulation, and we will explore where common outcomes can be achieved with those bodies in respect of public safety.

    As my period as Interim Director now closes, I reflect back with pride and admiration for the commitment and dedication demonstrated daily by everyone I have worked with, shared platforms with, and endured long meetings and workshops with to ensure that we drive forward all the critical work necessary to deliver on our objective.  I have rarely experienced such passion and desire to succeed which I believe is a reflection of how important Martyn’s Law is in contributing significantly to improvements in public safety and reducing the impact of terrorism.

    Continue Reading

  • Department stores try to distinguish themselves as beauty lovers turn to TikTok and Amazon

    Department stores try to distinguish themselves as beauty lovers turn to TikTok and Amazon

    NEW YORK — It’s shoppers like Quinn Kelsey who keep department store executives up at night.

    The 38-year-old Denver resident gets makeup ideas from TikTok videos and other social media content, not salespeople at beauty counters. She uses an AI chatbot to get product recommendations that fit her budget and to see how a certain foundation or lipstick would look on her. When she buys, it’s usually from Amazon.

    “I use Chat GPT as my personal beauty consultant,” Kelsey said. “Department stores? I’ll walk through one for the decor, but they’ve basically lost me unless I can get the same product-research experience there that I can get scrolling through my phone at home.”

    Once the ultimate beauty destination, department stores lost sales and their authority as skincare and makeup trendsetters starting in the late 1990s. That was when the growth of Sephora and Ulta Beauty made shopping for cosmetics more of a playful, self-service experience.

    But fast-changing consumer preferences have all types of retailers racing to outdo each other for a slice of the $129 billion U.S. beauty and personal care market. The competition is fiercer than ever due to the ease of e-commerce. Amazon, which has slowly added premium beauty brands to its massive selection, is the nation’s largest online seller of beauty and personal care products, according to market research company Euromonitor International.

    Social media also has provided new sources of beauty guidance. Instead of store advisers, many consumers look to videos by influencers, beauty brand founders or dermatologists for advice. Shoppers also turn to TikTok and Instagram for information about “dupes” — drugstore versions of more expensive products.

    “Stores are more of the showroom, but the spark itself is happening in TikTok,” Jake Bjorseth, founder of the Generation Z advertising agency Trndsttrs, said.

    To keep up, companies with both physical and online stores are investing in upgrades that are meant to give beauty fans like Kelsey an experience they can’t get anywhere else. Macy’s and Nordstrom, for example, renovated the beauty floors of their flagship New York stores to add more space, ultra-luxury brands and cutting-edge technology. At Nordstrom, customers can book an appointment to get robot-applied eyelash extensions for $170.

    The makeovers were launched in time for the holiday shopping season, which accounts for about one-quarter of all U.S. “prestige” beauty sales, according to market research firm Circana.

    Department stores chasing beauty sales are introducing some of the serve-yourself features of Sephora — Nordstrom put in a “beauty bar” with brightly lit mirrors where customers are allowed to take makeup from different counters — while trying to distinguish themselves from specialty and online rivals.

    Executives from Macy’s and Nordstrom said the latest changes were designed to create an engaging atmosphere that encourages shoppers to stay longer and spend more. The overhaul at Macy’s Herald Square included comfortable seating and skin analysis devices that help make the case for lotions and potions costing hundreds of dollars.

    In the Parfums de Marly section, customers sample scents while wearing a virtual reality headset meant to immerse them in an 18th century chateau the French fragrance maker cites as its inspiration.

    “This is the future of beauty,” Nicolette Bosco, Macy’s vice president of beauty, said, referring to the interactive technology the department store considers central to offering shoppers an elevated experience.

    The company expects to redesign the beauty departments of 40 more stores. The facelifts are intended to draw shoppers of all ages, Macy’s Inc. CEO Tony Spring said.

    “We’re trying very hard to take the idea of a department store and make it intimate and friendly and convenient,” he said.

    Since becoming chief executive of the department store’s parent company last year, Spring has focused on reviving Macy’s by trying to attract the higher-spending customers who power sales at Bloomingdale’s and upscale beauty retailer Bluemercury, both of which Macy’s owns.

    Nordstrom unwrapped the reimagined beauty floor of its midtown Manhattan store in September. It includes an area where shoppers can test beauty tools like LED light therapy masks and a “fragrance finder” machine that provide a dry whiff of up to 60 different scents.

    Nordstrom also expanded the beauty treatments area at the New York flagship and a few other stores to include a medical spa that provides Botox and dermal filler injections that cost $575 to $1,050.

    Sephora redefined beauty buying by installing mirrors and disposable application tools near compact displays of both tester products and ready-to-grab goods. The DIY concept was a major contrast from department store counters staffed by beauty advisers who oversaw product sampling and retrieved fresh products from locked drawers.

    But even innovators have to renovate. Sephora, a division of French luxury goods conglomerate LVMH, is in the process of updating its 720 stores in the U.S. and Canada.

    The stations where customers get their hair and makeup done are getting moved to the side for more privacy. The chain, known for its long cash register lines, plans to expedite check-outs by equipping salespeople with devices that accept card and contactless payments.

    Ulta, which stocks drugstore beauty brands like Maybelline as well as high-end brands, has had in-store hair salons since its founding in 1990. It’s adding ear piercing, testing robotic manicures and plans to add robotic lash extensions like Nordstrom’s to its service menu next year.

    Walmart has moved into the turf of specialty retailers and department stores with products from higher-end and independent brands. The nation’s largest retailer put beauty counters this year in 100 stores where customers can try products.

    After working at a fashion event at Nordstrom’s Manhattan flagship, Ivan Leon, a 35-year-old freelance stylist, headed to the Tom Ford fragrance counter. He walked away an hour later having spent $537 on two bottles of perfume: a unisex scent named Bitter Peach and another named Vanilla Sex.

    Leon planned to wear them together, a practice known as “fragrance layering” that he heard about on social media. The Nordstrom salesperson caught his interest by suggesting Tom Ford scents could be applied in tandem.

    “It’s kind of cool when you combine two scents and it makes something new,” Leon said. “I think it helps the psyche and builds confidence.”

    Leon, who typically buys his fragrances online, offers department stores hope but also represents the uphill climb they face given customers’ multidimensional shopping habits.

    TikTok is not only spawning trends like “tired girl” makeup and “blurred skin” but becoming a place where users discover and buy from new brands. TikTok Shop, an e-commerce feature the social media platform launched in 2023, has emerged as the nation’s seventh-largest online seller of beauty and personal care items, right behind Target, according to Euromonitor.

    The online market shares of Macy’s and Nordstrom are 1% and less than 0.5%, and declining, the market research firm said.

    Amazon, which accounts for almost half of online beauty and personal care sales, aims to mimic the physical store experience with virtual makeup try-on tools like one Sephora introduced in 2016. Sephora, meanwhile, unveiled in March an AI-powered online tool that uses selfies to identify potential skin concerns and make product recommendations.

    Continue Reading

  • Business investment in the UK

    7. Data sources and quality

    Quality and methodology information (QMI) on strengths, limitations, appropriate uses, and how the data were created is available in our Business investment QMI.

    Revisions

    In line with our National Accounts Revisions Policy, the data are open to revision from Quarter 1 (Jan to Mar) 2024 to Quarter 3 (July to Sept) 2025 for current price (CP) data and chained volume measure (CVM) estimates.

    We analyse and explain revisions performance for business investment up to and including the release of the Blue Book 2025 consistent dataset, published 30 September 2025, in our Business investment in the UK revisions in Blue Book: 2025 article.

    Data in this bulletin

    All data in this bulletin are presented in CVM, unless otherwise specified. This means the effect of price changes is removed from the data (in other words, the data are deflated).

    In Quarter 3 2025, the Quarterly Acquisitions and Disposals of Capital Assets Survey (QCAS) had a response rate of 76.3% for estimates used in the revised release. The QCAS is the largest data source for gross fixed capital formation (GFCF) and business investment.

    Adjustments

    Large capital expenditure is often reported later in the data collection period than smaller capital expenditure. This means that larger expenditures are often included in the revised (month three) results but are not reported in time for the provisional (month two) results. This can result in upward revisions in the later estimates for business investment and GFCF. Following investigation of the impact of this effect, a bias adjustment was introduced in the provisional estimate from Quarter 3 2013.

    This adjustment was suspended in Quarter 3 2020 because of uncertainties surrounding the effect of the coronavirus (COVID-19) pandemic. However, the bias adjustment was reintroduced to business investment and GFCF after further investigation and analysis of its impact since Quarter 4 (Oct to Dec) 2021. As usual, we have removed the bias adjustment for the revised release.

    Restarting of Producer Prices publications

    We restarted publication of our monthly business prices publications on 22 October 2025. Business prices data with corrected chain-linking methods and updated historical weights have been used in our monthly gross domestic product (GDP) datasets for Producer Price Indices (PPI), Import Price Indices (IPI), Export Price Indices (EPI), and Service Producer Price Indices (SPPI) in this release. The quarterly SPPI estimates are splined to months for use in monthly GDP calculations.

    These updates to business prices data will be incorporated in GDP estimates in line with our National Accounts Revisions Policy, becoming fully integrated for the entire time series in our Blue Book 2026 publication.

    Further information on the chain-linking error and the impact of methodological changes in the producer prices dataset are detailed in our Impact of correction to chain-linking methodology used in PPI and SPPI: October 2025 article.

    Accredited official statistics

    These accredited official statistics were independently reviewed by the Office for Statistics Regulation in September 2013. They comply with the standards of trustworthiness, quality and value in the Code of Practice for Statistics and should be labelled “accredited official statistics”.

    Back to table of contents

    Continue Reading

  • EBRD invests up to €50 million in Croatia’s leading bakery producer

    EBRD invests up to €50 million in Croatia’s leading bakery producer

    • EBRD investing up to €50 million to accelerate Mlinar’s regional growth and modernisation
    • Funding will support expansion, production upgrades and inclusive workplace initiatives
    • Mlinar further strengthening its position in the bakery sector across Croatia and CSEE region

    The European Bank for Reconstruction and Development (EBRD) has approved a landmark equity investment of up to €50 million in SEE Bakery International, the parent company of Mlinar Pekarska Industrija, Croatia’s leading producer of baked goods. This investment, which is structured in two tranches, will support Mlinar’s ambitious expansion and modernisation strategy across Croatia and the wider central, southern and eastern Europe (CSEE) region.

    The EBRD’s investment will further consolidate Mlinar’s position, supporting both organic growth and strategic mergers and acquisitions, and reinforcing its commitment to sustainability and gender inclusion. The EBRD’s commitment will enable Mlinar to expand its operations, enhance production capacity and pursue targeted acquisitions in the CSEE region. The investment will also drive energy-efficiency improvements and promote inclusive workplace practices, with a focus on supporting female migrant workers. This project is aligned with the EBRD’s country strategy for Croatia, its Food and Agribusiness Strategy 2025, and the Green Economy Transition Approach 2021-25

    Mlinar operates a multi-channel model, supplying major retailers and expanding its presence in the hotel, restaurant and catering segment. The company’s retail network spans Croatia, Serbia, Slovenia, and Bosnia and Herzegovina, with exports to over 20 markets worldwide. BOSQAR, the controlling shareholder of SEE Bakery International, is a leading Croatian investment group with a proven track record of driving growth and value creation across multiple sectors and is a longstanding client of the EBRD. BOSQAR is publicly listed on the Zagreb Stock Exchange and has stakes in companies operating in 23 countries, with diversified operations in sectors such as food, the outsourcing of business processes and technology, and human resources.

    Miljan Ždrale, the EBRD’s Regional Director for Central Europe, commented: “I am very pleased to see this deepening of the relationship with Mlinar and our longstanding partner BOSQAR. This investment will strengthen a flagship Croatian brand and accelerate its regional expansion and modernisation. Under strong leadership, Mlinar is well positioned to scale up production, pursue targeted acquisitions and deliver strong, sustainable growth. Our investment will also back energy‑efficiency upgrades and inclusive workplace practices, with a particular focus on supporting female migrant workers.”

    Natalia Zhukova, the EBRD’s Head of Food and Agribusiness, said: “We are pleased to support our client BOSQAR as they expand further in the food vertical through our investment in Mlinar’s ambitious growth strategy, which combines organic expansion with targeted acquisitions. We believe that, under BOSQAR’s strategic leadership, Mlinar is well positioned to accelerate its growth and create sustained value. Our investment will also support Mlinar’s energy-efficiency initiatives and help advance higher standards of employee inclusion.”

    Tamas Nagy, Co-Head of Private Equity at the EBRD, added: “This investment demonstrates the EBRD’s commitment to supporting high-growth companies with strong fundamentals and clear strategic direction. Mlinar’s growth story is testament to the transformative impact of strategic investment and partnership, and we are excited to join our longstanding partners BOSQAR and MidEuropa in supporting Mlinar’s ambitious plans. By supporting Mlinar’s expansion and modernisation, the EBRD is helping to strengthen the bakery sector’s resilience and competitiveness across Croatia and neighbouring markets.”

    “This investment marks a pivotal step in advancing Mlinar’s long-term growth strategy and further validates the strength of our operating model. The EBRD’s leadership in this round – and our ongoing partnership – reflects strong confidence in the progress we have achieved and the value we continue to create across our portfolio,” said Vanja Vlak, BOSQAR’s CFO.

    “The EBRD’s strategic entry into Mlinar validates the quality of our business model, financial performance and long-term potential. This represents a significant acknowledgment of the work we have done so far, as well as our strategic vision,” said Mladen Veber, President of the Board of Mlinar.

    “We are proud of Mlinar’s remarkable progress since its acquisition, which has enabled us to welcome two strong partners – BOSQAR and the EBRD – within the same year. This milestone reflects the strength of Mlinar’s trajectory and our shared vision for its future. We remain fully committed and look forward to working closely with both investors to further accelerate Mlinar’s growth,” said Filip Kisdobranski, a partner at MidEuropa (which was formerly the majority owner of Mlinar and is now a minority shareholder).

    This investment builds on a longstanding strategic partnership between the EBRD and BOSQAR, which has mobilised up to €150 million in equity and bond financing to date.

    The EBRD has invested more than €5 billion in Croatia to date across 275 projects. The Bank’s focus in Croatia is on supporting efforts to accelerate the reform process, leveraging the benefits of European Union accession to advance transition, and restructuring and commercialising public-sector enterprises.

    Continue Reading

  • NFU Scotland Urges Urgent Action as Dairy Crisis Deepens

    NFU Scotland Urges Urgent Action as Dairy Crisis Deepens

    NFU Scotland is calling for urgent support for Scottish dairy farmers facing a severe downturn in milk prices.

    Most farmers are now being paid less than it costs to produce their milk, forcing some to consider scaling back or exiting production altogether.

    NFU Scotland Vice President Robert Neill said:

    “We’ve seen highs and lows before, but the speed of this price drop is unprecedented. Farmers are under real pressure, and the supply chain must act responsibly.”

    While some farmers on organic or supermarket-aligned contracts are partially protected, many are fully exposed to market risks. Milk production in the UK and abroad has surged, driving prices down at a time when feed and input costs remain high.

    UK Farming Unions Send Warning to Processors

    In a show of unity, the four UK farming unions – including NFU Scotland – have written a joint letter to milk processors, urging fairness, transparency, and responsible behaviour.

    NFU Scotland Mike Committee Chair Bruce Mackie added:

    “Prices are falling fast while costs remain high. Processors must communicate clearly and fairly with suppliers. Farmers deserve transparency and trust during such a critical time.”

    The letter reminds buyers of their obligations under new Fair Dealing regulations, including the right for farmers to request a clear explanation of how prices are calculated. It also marks the first real test of the contract regulation adjudicator.

    Many farms invested heavily over the past two years. That spending supported the wider rural economy – but with income falling, servicing those investments is now a major concern.

    NFUS is also speaking directly with banks and retailers, calling for support and flexibility.

    Robert Neill added:

    “This is about more than milk it’s about rural jobs, local food security, and the future of our communities. The supply chain must share the risk, not just the reward.”

    Significant investments like Arla’s £144 million Lockerbie upgrade and growing export success show the sector’s long-term potential – but urgent help is needed now to make sure farms survive to benefit.

    Notes to editors:

    • A photograph of NFU Scotland Vice President Robert Neill is attached.
    • A link to the open letter to processors is available here.

    Ends

    Contact Carly Ross on 07860 642826


    Continue Reading

  • DFSA’s updated Crypto Token Framework : Clyde & Co

    DFSA’s updated Crypto Token Framework : Clyde & Co

    In our insights article of 5 November 2025, “The DFSA’s new crypto token proposal: A shift toward market-led oversight”, we outlined the regulator’s intention to move away from a prescriptive model of oversight. The Dubai Financial Services Authority (DFSA) has now formally updated its rules on Crypto Tokens in the DIFC, accompanied by supervisory guidelines and a policy statement issued on 15 December 2025. These changes will take effect on 12 January 2026.

    Key regulatory development

    Firms providing financial services involving crypto tokens must now determine, on a reasoned and documented basis, whether each token meets the DFSA’s suitability criteria. Responsibility for assessment is placed directly on market participants, with the expectation that firms will demonstrate compliance through structured processes and objective evidence.

    Supervisory guidelines: Core areas of assessment

    The supervisory guidelines set out how firms should approach suitability assessments. The evaluation is context-specific, meaning a token may be suitable for one activity or client base but not for another. Firms must consider the following areas:

    1. Token characteristics and governance arrangements and founders

    Under this criterion, firms are expected to assess whether a crypto token demonstrates a clear and practical use case, and whether its activity can be effectively traced and monitored on-chain on an ongoing basis.

    The regulator has provided explicit indicators to guide firms in conducting this suitability assessment. Notably, the DFSA highlights negative indicators, such as tokens that are purely speculative in nature; like meme coins, which lack real-world application or utility. A particular concern is the concentration of supply, in many cases, meme coins are heavily held by their founders or affiliates. This creates volatility, as large disposals of such holdings can cause severe and immediate price fluctuations.

    Conversely, the DFSA also identifies positive indicators. These include tokens with a genuine use case that addresses real-world problems, transparent governance arrangements, and the ability to monitor on-chain activity for compliance purposes. Tokens with a more diversified supply and limited concentration among a small group of holders are also viewed more favourably, as they reduce risks of market manipulation and enhance stability.

    2. Regulatory status

    Under the regulatory status criterion, firms are expected to consider whether a crypto token has been formally assessed or approved by regulators in other jurisdictions and whether its issuer is subject to ongoing supervision. A positive indicator would be a token that has been reviewed and approved for retail investor use under a comprehensive licensing regime. By contrast, a token that is merely listed on overseas exchanges or referenced in third party registration documents, without any express approval from a financial services regulator, would be regarded as a negative indicator.

    Equally important is the regulatory oversight of the issuer itself. Where the issuer is licensed and subject to ongoing supervision by a financial services regulator, including obligations around AML and KYC compliance, transaction monitoring, and reporting, this provides assurance of accountability and transparency. Such status can typically be verified through public registers and disclosures.

    Finally, firms should take into account whether the crypto token has been subject to enforcement actions, fines, or bans in any jurisdiction. A clean record with no history of regulatory sanctions is a strong positive indicator, whereas any evidence of enforcement measures would weigh against the token’s suitability. This focus on regulatory recognition and oversight ensures that only tokens with credible approval, transparent supervision, and a sound compliance history are considered appropriate.

    3. Market size and liquidity

    Under the market size and liquidity criterion, firms should evaluate the overall trading history and resilience of the crypto token’s market globally. This includes examining trading volumes, price volatility, and current market capitalisation. A strong token will demonstrate substantial market capitalisation relative to its trading volume and ecosystem size, reflecting broad adoption and liquidity. Stability in price and circulating supply further supports the token’s resilience and reduces susceptibility to manipulation, whereas markets dominated by a small number of holders present heightened investment and liquidity risks.

    Equally important is the ability to accurately price the token. Tokens that are actively traded across multiple exchanges with sufficient liquidity and transparent market prices provide confidence in valuation. In contrast, tokens that are highly volatile and easily influenced by a small number of trades undermine pricing reliability and increase risk and are therefore viewed negatively by the regulator.

    Finally, transparency of supply metrics is a critical factor. Suitable tokens will have their total, circulating, and maximum supply clearly disclosed and verifiable on-chain, with consistency across blockchain explorers and whitepapers. This transparency reduces risks of inflation or dilution and ensures investors have reliable information to support decision making. Together, these elements trading history, capitalisation, volatility, and supply transparency form the foundation for assessing whether a crypto token’s market is sufficiently robust and liquid to be considered suitable for the DIFC.

    4. Technology resilience

    Under the technology resilience criterion, firms should assess both the maturity and stability of the blockchain on which the crypto token is issued, as well as its ability to respond to adverse technological incidents. A strong token will be supported by a well established blockchain network that has been operational for several years, demonstrating high uptime and resilience with no major security breaches or crisis events. Such networks typically maintain thousands of geographically distributed nodes, benefit from strong community support, and have a proven track record of processing transactions reliably and securely over time.

    Equally important is the blockchain’s capacity to adapt to cyber incidents. Suitable tokens are built on networks with established incident response procedures, a history of patching vulnerabilities quickly, and transparent communication with users during security events. Protocols that include upgradability features and have successfully coordinated community responses to mitigate past cyber attacks provide further assurance of resilience. In contrast, tokens lacking formal mechanisms for responding to technological incidents, or those that have demonstrated poor preparedness during recent attacks, highlight significant risks.

    Taken together, the maturity of the blockchain and its demonstrated ability to withstand and adapt to technological challenges are critical indicators of whether a crypto token can be considered robust and suitable.

    5. Compliance with DFSA rules

    Under the compliance with DFSA rules criterion, firms should assess whether the use of a crypto token enables them to meet all obligations under DFSA administered laws and rules, with particular emphasis on AML and KYC requirements. A suitable token will operate transparently, allowing transactions to be monitored on chain and supporting mechanisms such as KYC and transaction screening where required. This ensures that firms can maintain effective oversight of activity and demonstrate adherence to the DFSA’s regulatory standards. By contrast, if the design or technical features of a token obstruct transparency or prevent effective monitoring, its use could inhibit compliance and therefore render it unsuitable. The key consideration is whether the token’s structure and functionality align with the regulatory framework, enabling firms to uphold their obligations without compromise.

    Practical implications for firms

    The updated regime introduces a more structured and predictable pathway for Crypto Token activities in the DIFC. Firms must:

    • Establish internal frameworks for assessing token suitability.
    • Document reasoning and evidence supporting their conclusions.
    • Implement monitoring processes for compliance, market activity, and technological resilience.
    • Differentiate assessments according to client segments and business models.
    • While firms may take into account another participant’s suitability assessment, they remain responsible for their own determination.

    The DFSA’s updated framework shifts the burden of judgment squarely onto firms. This means companies can no longer rely on regulatory pre clearance or industry consensus; they must build defensible, evidence based processes for each token they touch. In practice, that requires not only documenting why a token meets suitability criteria but also showing how ongoing monitoring will catch changes in governance, liquidity, or regulatory status. Firms that treat this as a one off exercise risk falling short what the DFSA expects is a living framework that evolves with the market.

    Conclusion

    The DFSA’s updated framework represents a significant development in the regulation of digital assets within the DIFC. By placing responsibility on firms to assess suitability, the regime promotes accountability and ensures that oversight reflects the realities of market activity. As the rules come into force in January 2026, firms should prepare to adopt rigorous, well-documented processes that align with the DFSA’s expectations and support the continued growth of a safe and well-regulated crypto environment.

    Our team is advising clients across sectors on regulatory compliance, infrastructure, and risks. If you would like to discuss how these reforms affect your business or how to turn regulatory change into competitive edge; get in touch with Tom Bicknell, Barkha Doshi.

     

    Continue Reading

  • A year of regeneration in Walsall town centre

    A year of regeneration in Walsall town centre

    Published on

    Over £70million in total has been secured to transform Walsall Town Centre, including the £20.25million Community Regeneration Partnership (CRP) funding that was secured in February 2025, and the last 12 months have seen Walsall’s transformation gather pace.

    The borough of Walsall is in the middle of a £1.5billion programme of transformation; delivering a bold future built on proud foundations.  

    Several major regeneration projects across the town centre have moved from planning into delivery; from revitalising long-neglected retail space to improving connectivity, public realm and community facilities, and local people are beginning to see real changes.

    CGI of the Saddlers Centre entrance

    Reviving the Town Centre

    At the heart of Walsall’s town-centre regeneration stands the Connected Gateway Project, a transformational scheme that will reconnect the bus and rail hubs, modernise retail and public space, and reshape the arrival experience into Walsall town centre.

    A major milestone was reached in October 2025 when work on the first phase of the project was completed. The ground floor (Bradford Mall) of the Saddlers Centre was fully refurbished and Walsall residents even welcomed back the much-loved Three Men in a Boat automaton as part of the work.

    2025 also saw contractor Keir being appointed to deliver the second phase of the scheme, which will see the continued redevelopment of the Saddlers Centre (Park Mall) as well as the demolition of buildings on Park Street (in early 2026) to create a new plaza and improve the linkages between St Paul’s Bus Station and Walsall’s train station.

    Connecting the Waterfront: Canal Footbridge & Sister Dora Boat 

    A new Walsall waterfront footbridge is expected to improve pedestrian links between the waterside/residential apartments south of Walsall’s Canal Basin with Crown Wharf retail park (and on into the town centre). This will begin delivery in early 2026, bringing the residents more fully into the fabric of town-centre life. 

    In November 2025 we saw the launch of a new canal maintenance barge, the “Sister Dora”, which will be moored in the town’s canal basin. The barge, operated by the Canal & River Trust, will help keep clean the waterways and towpaths around Walsall and shows Walsall’s commitment to reinvigorating its canals and making them assets for leisure, residents and visitors alike.

    A large canal footbridge

    The proposed canal footbridge will be installed in 2026 near The Light Cinema

    Historic Building Renewal: The Guildhall Walsall

    Another key success of 2025 has been the continuing restoration and refurbishment of The Guildhall Walsall – one of the town’s most recognisable civic buildings. The much-anticipated restoration and transformation of Walsall’s grade II* listed Guildhall started in May 2025, with completion expected in summer 2026. The building will then be managed as a Creative Industries Enterprise Centre by Urban Hax CIC, and is already being marketed as “The Guildhall” to potential users and investors.

    The refurbished building will have enhanced its long-term sustainability, with improved accessibility, and will create modern, flexible internal spaces for creative industry businesses, with spaces for community activity and events. This investment ensures that The Guildhall Walsall will continue to play an active role in town-centre life for generations to come.

    Urban Hax, Cllr Andrew and Des O'Neil stand in front of the construction hoardings around the Guildhall

    Construction on the historic Guildhall will complete ready for a Summer 2026 opening

    Young people, Education and Skills Investment: New Adult Learning Centre and Youth Hub

    In one of the most exciting repurposing projects for the town centre, planning permission has now been granted for a new Adult Learning Centre to be delivered within the former Marks & Spencer building on Park Street.

    The state-of-the-art facility will support skills development, employability and lifelong learning, benefitting adults from across the borough, bringing more footfall into the town centre. Work has already started to strip out the old parts of the building and construction is due to begin in 2026, with the centre expected to open to students in September 2027.

    July also saw a new youth hub open in the Saddlers Centre in Walsall, named by our young people as ‘Our Place’, with the aim of giving people under 18 years old  a safe and welcoming place to go after school and throughout the school holidays. The centre has seen over 1,300 visits from young people since its opening.

    WM Mayor, Cllr Andrew and young people

    The Youth Hub in the Saddlers Centre

    A New Strategic Vision Approved

    A new Town Centre Framework was formally approved by Cabinet in December 2025, setting out a long-term vision for Walsall as one of the healthiest, greenest and most accessible town centres in the country. This strategic blueprint guides future development, public realm improvements, heritage assets, markets, active travel, community provision and investment in leisure, culture and living.

    This framework provides a blueprint for the next 15–20 years of regeneration with many of the initiatives already underway.

    Looking ahead to 2026 

    As major projects move further into delivery through 2026–27, residents can expect to see even more visible signs of the transformation taking place across the town centre.

    Walsall’s regeneration programme will continue to be shaped by community feedback, strong partnerships and long-term strategic planning, ensuring that this £multi-million investment delivers real social, economic and cultural value for people and businesses across the district.

    “ The past year has been truly transformational for Walsall. We are seeing major regeneration schemes move from paper into delivery, and residents can now feel and see positive change taking shape. Whether it’s the refurbishment of Bradford Mall, the return of Three Men In a Boat, the renewal of the Guildhall, the planned canal footbridge, or the arrival of the new Adult Learning Centre, these projects show our long-term commitment to building a thriving town centre that serves local people. With more investment still to come, the next two years will be even more exciting. “

    Continue Reading

  • In win for Indonesia islanders, Swiss court upholds climate action against Holcim

    In win for Indonesia islanders, Swiss court upholds climate action against Holcim


    Swiss court agrees to hear a landmark climate lawsuit against Holcim, as Indonesian islanders seek compensation, CO2 emission cuts and climate adaptation measures.


    Keystone-SDA

    The Zug Cantonal Court has ruled in favour of a climate lawsuit against Holcim, marking a legal first in Switzerland. Residents of an Indonesian island are demanding compensation from the cement company, a significant reduction in CO2 emissions and participation in adaptation measures.

    +Get the most important news from Switzerland in your inbox

    The court has recognised that the plaintiffs deserve legal protection as people whose livelihoods are affected by climate change, the aid organisation of the Swiss Protestant Reformed Church (HEKS) announced on Monday.

    More

    Mrs Asmania

    More


    Climate adaptation

    Four Indonesian islanders take on Swiss cement giant Holcim




    This content was published on




    A report from Pulau Pari, Indonesia, where four residents have vowed to fight a major Swiss company in one of the world’s most polluting industries.


    Read more: Four Indonesian islanders take on Swiss cement giant Holcim

    Four inhabitants of the island of Pari filed the lawsuit against Holcim. They argue that the flooding caused by climate change is threatening the livelihoods of the islanders.

    + Holcim’s Uganda unit accused of human rights and environmental abuses

    Holcim plans to appeal the decision. At a hearing in September, the company rejected the plaintiffs’ claims, arguing it is affected by climate change to the same extent as the global population and that the case shows no concrete, legally protectable interest. Holcim added that it remains committed to achieving net zero emissions by 2050.

    Adapted from German by DeepL/ds

    We select the most relevant news for an international audience and use automatic translation tools to translate them into English. A journalist then reviews the translation for clarity and accuracy before publication.  

    Providing you with automatically translated news gives us the time to write more in-depth articles. The news stories we select have been written and carefully fact-checked by an external editorial team from news agencies such as Bloomberg or Keystone.

    If you have any questions about how we work, write to us at english@swissinfo.ch

    Continue Reading